secwatch.observer — SEC 8-K summary
======================================

Issuer:     Medtronic plc (MDT)
CIK:        0001613103
Form:       8-K
Filed at:   2021-10-15T23:59:59+00:00
Accession:  0001613103-21-000047
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Medtronic SPYRAL HTN-ON MED study DSMB recommends trial continuation; full cohort follow-up expected H2 2022
--------------------------------------------------------------------------------

- DSMB prespecified interim analysis recommends ON MED clinical trial enrollment continue until full sample size of 260 patients is reached.
- Full cohort follow-up expected in H2 2022; trial powered to detect statistically significant therapeutic benefit at final analysis.
- Medtronic reiterates FY2022 revenue and EPS guidance; long-range plan of 5%+ organic revenue growth and 8%+ adjusted EPS growth unchanged.
- Company projects global renal denervation market exceeding $500M by 2026 and $2-3B by 2030.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1613103/000161310321000047/0001613103-21-000047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1613103/000161310321000047/mdt-20211015.htm
  HTML page:      https://secwatch.observer/filing/0001613103-21-000047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer